{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T06:56:35Z","timestamp":1790492195697,"version":"4.1.0"},"reference-count":131,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"CIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","thrombosisresearch.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.thromres.2018.02.135","type":"journal-article","created":{"date-parts":[[2018,2,20]],"date-time":"2018-02-20T01:57:01Z","timestamp":1519091821000},"page":"54-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Role of plasminogen activator inhibitor-1 in coronary pathophysiology"],"prefix":"10.1016","volume":"164","author":[{"given":"Richard G.","family":"Jung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Simard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisha","family":"Labinaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Daniel","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Di Santo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pouya","family":"Motazedian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Rochman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Gaudet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Ali","family":"Faraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob S.B.","family":"Beanlands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0906-1363","authenticated-orcid":false,"given":"Benjamin","family":"Hibbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2018.02.135_bb0005","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cjca.2013.09.012","article-title":"The evolution of coronary stents: a brief review","volume":"30","author":"Simard","year":"2014","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.thromres.2018.02.135_bb0010","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1084\/jem.20060217","article-title":"Are hemostasis and thrombosis two sides of the same coin?","volume":"203","author":"Colman","year":"2006","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.thromres.2018.02.135_bb0015","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0140-6736(09)60040-4","article-title":"Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited","volume":"373","author":"Watson","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2018.02.135_bb0020","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.blre.2011.03.002","article-title":"Platelets at work in primary hemostasis","volume":"25","author":"Broos","year":"2011","journal-title":"Blood Rev."},{"key":"10.1016\/j.thromres.2018.02.135_bb0025","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.thromres.2011.11.040","article-title":"Factor XIII, clot structure, thrombosis","volume":"129","author":"Bagoly","year":"2012","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2018.02.135_bb0030","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.blre.2014.09.003","article-title":"Fibrinolysis and the control of blood coagulation","volume":"29","author":"Chapin","year":"2015","journal-title":"Blood Rev."},{"key":"10.1016\/j.thromres.2018.02.135_bb0035","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1016\/S0021-9258(19)81051-7","article-title":"Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin","volume":"257","author":"Hoylaerts","year":"1982","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.thromres.2018.02.135_bb0040","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0268-9499(95)80015-8","article-title":"Structure of plasminogen activator inhibitor 1 (PAI-1) and its function in fibrinolysis: an update","volume":"9","author":"van Meijer","year":"1995","journal-title":"Fibrinolysis"},{"key":"10.1016\/j.thromres.2018.02.135_bb0045","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.coph.2005.01.007","article-title":"Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease","volume":"5","author":"De Taeye","year":"2005","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.thromres.2018.02.135_bb0050","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/0140-6736(93)92062-X","article-title":"Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study","volume":"342","author":"Meade","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2018.02.135_bb0055","first-page":"56","article-title":"Plasminogen activator inhibitor 1: physiological and pathophysiological roles","volume":"17","author":"Binder","year":"2002","journal-title":"News Physiol. Sci."},{"key":"10.1016\/j.thromres.2018.02.135_bb0060","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1101\/SQB.1987.052.01.060","article-title":"The serpins: evolution and adaptation in a family of protease inhibitors","volume":"52","author":"Carrell","year":"1987","journal-title":"Cold Spring Harb. Symp. Quant. Biol."},{"key":"10.1016\/j.thromres.2018.02.135_bb0065","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1111\/j.1538-7836.2005.01420.x","article-title":"PAI-1 and atherothrombosis","volume":"3","author":"Vaughan","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2018.02.135_bb0070","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1432-1033.1988.tb14320.x","article-title":"The organization of the human-plasminogen-activator-inhibitor-1 gene. Implications on the evolution of the serine-protease inhibitor family","volume":"176","author":"Strandberg","year":"1988","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.thromres.2018.02.135_bb0075","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0268-9499(91)90001-K","article-title":"Regulation of PAI-1 gene expression","volume":"5","author":"Loskutoff","year":"1991","journal-title":"Fibrinolysis"},{"key":"10.1016\/j.thromres.2018.02.135_bb0080","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1021\/bi00387a004","article-title":"Structure of the human plasminogen activator inhibitor 1 gene: nonrandom distribution of introns","volume":"26","author":"Loskutoff","year":"1987","journal-title":"Biochemistry"},{"key":"10.1016\/j.thromres.2018.02.135_bb0085","first-page":"336","article-title":"Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator Inhibitor-1 production","volume":"85","author":"Brown","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.thromres.2018.02.135_bb0090","doi-asserted-by":"crossref","first-page":"5525","DOI":"10.1073\/pnas.85.15.5525","article-title":"Type 1 plasminogen activator inhibitor gene: functional analysis and glucocorticoid regulation of its promoter","volume":"85","author":"van Zonneveld","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.thromres.2018.02.135_bb0095","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1161\/01.HYP.37.5.1336","article-title":"Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes in primary culture","volume":"37","author":"Skurk","year":"2001","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.thromres.2018.02.135_bb0100","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1046\/j.1523-1755.2000.00277.x","article-title":"Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo","volume":"58","author":"Brown","year":"2000","journal-title":"Kidney Int."},{"key":"10.1016\/j.thromres.2018.02.135_bb0105","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1161\/01.ATV.18.1.20","article-title":"Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia","volume":"18","author":"Eriksson","year":"1998","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.thromres.2018.02.135_bb0110","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1007\/s00125-015-3525-8","article-title":"Pathophysiology of diabetic dyslipidaemia: where are we?","volume":"58","author":"Verges","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.thromres.2018.02.135_bb0115","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1161\/01.ATV.0000032134.92180.41","article-title":"Early kinetic abnormalities of apoB-containing lipoproteins in insulin-resistant women with abdominal obesity","volume":"22","author":"Pont","year":"2002","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.thromres.2018.02.135_bb0120","doi-asserted-by":"crossref","first-page":"8225","DOI":"10.1074\/jbc.273.14.8225","article-title":"Sp1 sites mediate activation of the plasminogen activator Inhibitor-1 promoter by glucose in vascular smooth muscle cells","volume":"273","author":"Chen","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.thromres.2018.02.135_bb0125","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004918","article-title":"Causal effect of plasminogen activator inhibitor type 1 on coronary heart disease","volume":"6","author":"Song","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.thromres.2018.02.135_bb0130","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1093\/emboj\/17.11.3091","article-title":"Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene","volume":"17","author":"Dennler","year":"1998","journal-title":"EMBO J."},{"key":"10.1016\/j.thromres.2018.02.135_bb0135","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1093\/nar\/23.18.3710","article-title":"Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53","volume":"23","author":"Kunz","year":"1995","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.thromres.2018.02.135_bb0140","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1161\/hc5001.100793","article-title":"Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: a systematic review","volume":"104","author":"Boekholdt","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2018.02.135_bb0145","doi-asserted-by":"crossref","first-page":"4873","DOI":"10.1182\/blood-2012-06-436188","article-title":"Genome-wide association study for circulating levels of PAI-1 provides novel insights into its regulation","volume":"120","author":"Huang","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2018.02.135_bb0150","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1160\/TH09-10-0702","article-title":"4G\/5G polymorphism and haplotypes of SERPINE1 in atherosclerotic diseases of coronary arteries","volume":"103","author":"Koch","year":"2010","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2018.02.135_bb0155","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/MOL.0b013e32814e6d29","article-title":"Plasminogen activator inhibitor-1, adipose tissue and insulin resistance","volume":"18","author":"Alessi","year":"2007","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.thromres.2018.02.135_bb0160","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1161\/01.ATV.0000242905.41404.68","article-title":"PAI-1 and the metabolic syndrome: links, causes, and consequences","volume":"26","author":"Alessi","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.thromres.2018.02.135_bb0165","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1365-2796.1990.tb00157.x","article-title":"Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease","volume":"227","author":"Landin","year":"1990","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.thromres.2018.02.135_bb0170","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3346\/jkms.2000.15.2.146","article-title":"Plasminogen activator inhibitor-1 4G\/5G promoter polymorphism and coagulation factor VII Arg353-->Gln polymorphism in Korean patients with coronary artery disease","volume":"15","author":"Song","year":"2000","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.thromres.2018.02.135_bb0175","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1055\/s-0038-1646598","article-title":"Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients--relationship with plasma insulin","volume":"61","author":"Juhan-Vague","year":"1989","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2018.02.135_bb0180","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1055\/s-0037-1615353","article-title":"Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction--the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction","volume":"80","author":"Scarabin","year":"1998","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2018.02.135_bb0185","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1161\/STROKEAHA.111.622217","article-title":"Plasminogen activator inhibitor-1 and thrombotic cerebrovascular diseases","volume":"43","author":"Tjarnlund-Wolf","year":"2012","journal-title":"Stroke"},{"key":"10.1016\/j.thromres.2018.02.135_bb0190","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1515\/cclm-2013-1124","article-title":"The association between plasminogen activator inhibitor type 1 (PAI-1) levels, PAI-1 4G\/5G polymorphism, and myocardial infarction: a Mendelian randomization meta-analysis","volume":"52","author":"Nikolopoulos","year":"2014","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.thromres.2018.02.135_bb0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026762","article-title":"Platelets retain high levels of active plasminogen activator inhibitor 1","volume":"6","author":"Brogren","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.thromres.2018.02.135_bb0200","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1172\/JCI112761","article-title":"cDNA cloning of human plasminogen activator-inhibitor from endothelial cells","volume":"78","author":"Ginsburg","year":"1986","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.thromres.2018.02.135_bb0205","doi-asserted-by":"crossref","first-page":"14914","DOI":"10.1016\/S0021-9258(17)42691-3","article-title":"Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells","volume":"259","author":"van Mourik","year":"1984","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.thromres.2018.02.135_bb0210","doi-asserted-by":"crossref","first-page":"29709","DOI":"10.1074\/jbc.M111.236554","article-title":"Crystal structure of plasminogen activator inhibitor-1 in an active conformation with normal thermodynamic stability","volume":"286","author":"Jensen","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.thromres.2018.02.135_bb0215","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/B978-0-12-386471-0.00005-5","article-title":"Use of mouse models to study plasminogen activator inhibitor-1","volume":"499","author":"Declerck","year":"2011","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.thromres.2018.02.135_bb0220","doi-asserted-by":"crossref","first-page":"7588","DOI":"10.1016\/S0021-9258(18)42557-4","article-title":"Saturation mutagenesis of the plasminogen activator inhibitor-1 reactive center","volume":"267","author":"Sherman","year":"1992","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.thromres.2018.02.135_bb0225","doi-asserted-by":"crossref","first-page":"7027","DOI":"10.1074\/jbc.M110.204537","article-title":"Structural basis for recognition of urokinase-type plasminogen activator by plasminogen activator inhibitor-1","volume":"286","author":"Lin","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.thromres.2018.02.135_bb0230","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jsb.2008.11.001","article-title":"High quality structure of cleaved PAI-1-stab","volume":"165","author":"Dewilde","year":"2009","journal-title":"J. Struct. Biol."},{"key":"10.1016\/j.thromres.2018.02.135_bb0235","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1432-1033.1989.tb15238.x","article-title":"Purification of active human plasminogen activator inhibitor 1 from Escherichia coli. Comparison with natural and recombinant forms purified from eucaryotic cells","volume":"186","author":"Lawrence","year":"1989","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.thromres.2018.02.135_bb0240","doi-asserted-by":"crossref","DOI":"10.1038\/srep17714","article-title":"Plasminogen activator inhibitor-1 and type 2 diabetes: a systematic review and meta-analysis of observational studies","volume":"6","author":"Yarmolinsky","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.thromres.2018.02.135_bb0245","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/jcp.22783","article-title":"PAI-1 in tissue fibrosis","volume":"227","author":"Ghosh","year":"2012","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.thromres.2018.02.135_bb0250","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1182\/blood.V70.4.1090.1090","article-title":"Conversion of the active to latent plasminogen activator inhibitor from human endothelial cells","volume":"70","author":"Levin","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2018.02.135_bb0255","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1749-6632.1990.tb42296.x","article-title":"The fibrinolytic system of the vessel wall and its role in the control of thrombosis","volume":"598","author":"Loskutoff","year":"1990","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.thromres.2018.02.135_bb0260","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1182\/blood.V70.5.1645.1645","article-title":"Plasminogen activator inhibitor 1: development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation","volume":"70","author":"Kruithof","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2018.02.135_bb0265","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1749-6632.1992.tb51599.x","article-title":"Lysis of platelet-rich thrombi: the role of PAI-1","volume":"667","author":"Booth","year":"1992","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.thromres.2018.02.135_bb0270","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1182\/blood.V77.9.1949.1949","article-title":"The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia","volume":"77","author":"Sakata","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2018.02.135_bb0275","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.2174\/0929867043364595","article-title":"Plasminogen activator inhibitor-1","volume":"11","author":"Gils","year":"2004","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.thromres.2018.02.135_bb0280","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1432-1033.1994.tb20003.x","article-title":"Purification and characterization of active and stable recombinant plasminogen-activator inhibitor accumulated at high levels in Escherichia coli","volume":"224","author":"Sancho","year":"1994","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.thromres.2018.02.135_bb0285","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0014-5793(02)02830-2","article-title":"The vitronectin binding area of plasminogen activator inhibitor-1, mapped by mutagenesis and protection against an inactivating organochemical ligand","volume":"521","author":"Jensen","year":"2002","journal-title":"FEBS Lett."},{"key":"10.1016\/j.thromres.2018.02.135_bb0290","doi-asserted-by":"crossref","first-page":"17914","DOI":"10.1074\/jbc.M314197200","article-title":"Conservation of critical functional domains in murine plasminogen activator inhibitor-1","volume":"279","author":"Xu","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.thromres.2018.02.135_bb0295","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nsb943","article-title":"How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration","volume":"10","author":"Zhou","year":"2003","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.thromres.2018.02.135_bb0300","first-page":"787","article-title":"Constitutive and regulated expression of vitronectin","volume":"12","author":"Seiffert","year":"1997","journal-title":"Histol. Histopathol."},{"key":"10.1016\/j.thromres.2018.02.135_bb0305","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1111\/jth.13869","article-title":"Plasminogen activator Inhibitor-1 regulates the vascular expression of vitronectin","volume":"15","author":"Luo","year":"2017","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2018.02.135_bb0310","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1126\/science.1161748","article-title":"Membrane fusion: grappling with SNARE and SM proteins","volume":"323","author":"Sudhof","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.thromres.2018.02.135_bb0315","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.blre.2009.04.001","article-title":"Platelet alpha-granules: basic biology and clinical correlates","volume":"23","author":"Blair","year":"2009","journal-title":"Blood Rev."},{"key":"10.1016\/j.thromres.2018.02.135_bb0320","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1055\/s-0038-1650232","article-title":"Proteins of the fibrinolytic system in human thrombi","volume":"75","author":"Robbie","year":"1996","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2018.02.135_bb0325","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1161\/01.ATV.16.10.1277","article-title":"High concentrations of active plasminogen activator inhibitor-1 in porcine coronary artery thrombi","volume":"16","author":"Fay","year":"1996","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.thromres.2018.02.135_bb0330","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1182\/blood.V83.2.351.351","article-title":"Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1-dependent and -independent mechanisms","volume":"83","author":"Fay","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2018.02.135_bb0335","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/0006-291X(89)92490-X","article-title":"Circulating human blood platelets retain appreciable amounts of poly (A)+ RNA","volume":"160","author":"Roth","year":"1989","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.thromres.2018.02.135_bb0340","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1182\/blood-2004-04-1439","article-title":"Platelets synthesize large amounts of active plasminogen activator inhibitor 1","volume":"104","author":"Brogren","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2018.02.135_bb0345","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/nsmb.1651","article-title":"Existence of a microRNA pathway in anucleate platelets","volume":"16","author":"Landry","year":"2009","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.thromres.2018.02.135_bb0350","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1160\/TH14-07-0622","article-title":"Dissociation of SERPINE1 mRNA from the translational repressor proteins Ago2 and TIA-1 upon platelet activation","volume":"113","author":"Corduan","year":"2015","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2018.02.135_bb0355","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1055\/s-2004-833484","article-title":"Change in protein phenotype without a nucleus: translational control in platelets","volume":"30","author":"Weyrich","year":"2004","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.thromres.2018.02.135_bb0360","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1128\/MCB.26.8.3295-3307.2006","article-title":"Translational control of cytochrome c by RNA-binding proteins TIA-1 and HuR","volume":"26","author":"Kawai","year":"2006","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.thromres.2018.02.135_bb0365","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/(SICI)1096-9896(200002)190:3<300::AID-PATH596>3.0.CO;2-I","article-title":"Molecular mechanisms in intimal hyperplasia","volume":"190","author":"Newby","year":"2000","journal-title":"J. Pathol."},{"key":"10.1016\/j.thromres.2018.02.135_bb0370","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1161\/ATVBAHA.116.308344","article-title":"Pharmacological targeting of plasminogen activator inhibitor-1 decreases vascular smooth muscle cell migration and neointima formation","volume":"36","author":"Ji","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.thromres.2018.02.135_bb0375","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/562481","article-title":"PAI-1: an integrator of cell signaling and migration","volume":"2011","author":"Czekay","year":"2011","journal-title":"Int. J. Cell Biol."},{"key":"10.1016\/j.thromres.2018.02.135_bb0380","doi-asserted-by":"crossref","first-page":"22595","DOI":"10.1074\/jbc.M313004200","article-title":"The low density lipoprotein receptor-related protein is a motogenic receptor for plasminogen activator inhibitor-1","volume":"279","author":"Degryse","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.thromres.2018.02.135_bb0385","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1160\/TH14-08-0678","article-title":"PAI-1 modulates cell migration in a LRP1-dependent manner via beta-catenin and ERK1\/2","volume":"113","author":"Kozlova","year":"2015","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2018.02.135_bb0390","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S0021-9258(19)85032-9","article-title":"Purification of a protein from bovine plasma that binds to type 1 plasminogen activator inhibitor and prevents its interaction with extracellular matrix. Evidence that the protein is vitronectin","volume":"264","author":"Mimuro","year":"1989","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.thromres.2018.02.135_bb0395","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1161\/01.CIR.98.21.2241","article-title":"High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor","volume":"98","author":"Thogersen","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2018.02.135_bb0400","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1161\/01.STR.31.1.26","article-title":"Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator\/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke","volume":"31","author":"Johansson","year":"2000","journal-title":"Stroke"},{"key":"10.1016\/j.thromres.2018.02.135_bb0405","doi-asserted-by":"crossref","first-page":"530","DOI":"10.2337\/diabetes.55.02.06.db05-1041","article-title":"Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study","volume":"55","author":"Meigs","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.thromres.2018.02.135_bb0410","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11892-006-0052-5","article-title":"Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes","volume":"6","author":"Trost","year":"2006","journal-title":"Curr. Diab. Rep."},{"key":"10.1016\/j.thromres.2018.02.135_bb0415","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1161\/01.ATV.0000091250.53231.4D","article-title":"Intramural plasminogen activator inhibitor type-1 and coronary atherosclerosis","volume":"23","author":"Sobel","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.thromres.2018.02.135_bb0420","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1161\/ATVBAHA.107.160168","article-title":"Plasminogen activator inhibitor-1 activity in type 2 diabetes: a different relationship with coronary heart disease and diabetic retinopathy","volume":"28","author":"Brazionis","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.thromres.2018.02.135_bb0425","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/blood-2013-07-517060","article-title":"Human circadian system causes a morning peak in prothrombotic plasminogen activator inhibitor-1 (PAI-1) independent of the sleep\/wake cycle","volume":"123","author":"Scheer","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2018.02.135_bb0430","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1046\/j.1365-2141.1997.d01-2137.x","article-title":"The effects of chronic smoking on the fibrinolytic potential of plasma and platelets","volume":"97","author":"Simpson","year":"1997","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.thromres.2018.02.135_bb0435","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1249\/01.MSS.0000145447.61736.ED","article-title":"Temporal changes in tPA and PAI-1 after maximal exercise","volume":"36","author":"Cooper","year":"2004","journal-title":"Med. Sci. Sports Exerc."},{"key":"10.1016\/j.thromres.2018.02.135_bb0440","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0021-9150(98)00108-7","article-title":"Increased PAI activity and PAI-1 antigen occurring with an oral fat load: associations with PAI-1 genotype and plasma active TGF-beta levels","volume":"140","author":"Byrne","year":"1998","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.thromres.2018.02.135_bb0445","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1182\/blood.V71.1.220.220","article-title":"Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay","volume":"71","author":"Declerck","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2018.02.135_bb0450","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1055\/s-0037-1615189","article-title":"Modulation of plasminogen activator inhibitor 1 by Triton X-100--identification of two consecutive conformational transitions","volume":"80","author":"Gils","year":"1998","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2018.02.135_bb0455","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1055\/s-0037-1614487","article-title":"Solvent effects on activity and conformation of plasminogen activator inhibitor-1","volume":"81","author":"Andreasen","year":"1999","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2018.02.135_bb0460","doi-asserted-by":"crossref","first-page":"11581","DOI":"10.1016\/S0021-9258(17)39071-3","article-title":"Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants","volume":"260","author":"Hekman","year":"1985","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.thromres.2018.02.135_bb0465","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171271","article-title":"The effects of residual platelets in plasma on plasminogen activator inhibitor-1 and plasminogen activator inhibitor-1-related assays","volume":"12","author":"Pieters","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.thromres.2018.02.135_bb0470","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/0268-9499(94)90279-8","article-title":"The influence of centrifugation load on platelet number and PAI-1 antigen concentration in human plasma","volume":"8 (","author":"Sidelmann","year":"1994","journal-title":"Fibrinolysis"},{"key":"10.1016\/j.thromres.2018.02.135_bb0475","first-page":"312","article-title":"PAI-1 antagonists: the promise and the peril","volume":"122","author":"Vaughan","year":"2011","journal-title":"Trans. Am. Clin. Climatol. Assoc."},{"key":"10.1016\/j.thromres.2018.02.135_bb0480","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1055\/s-0038-1657607","article-title":"PAI-1, obesity, insulin resistance and risk of cardiovascular events","volume":"78","author":"Juhan-Vague","year":"1997","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2018.02.135_bb0485","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1161\/hq0102.101552","article-title":"Stromal cells are the main plasminogen activator inhibitor-1-producing cells in human fat: evidence of differences between visceral and subcutaneous deposits","volume":"22","author":"Bastelica","year":"2002","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.thromres.2018.02.135_bb0490","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1096\/fj.00-0750fje","article-title":"Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob\/ob mice","volume":"15","author":"Schafer","year":"2001","journal-title":"FASEB J."},{"key":"10.1016\/j.thromres.2018.02.135_bb0495","doi-asserted-by":"crossref","first-page":"336","DOI":"10.2337\/diabetes.53.2.336","article-title":"Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1","volume":"53","author":"Ma","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.thromres.2018.02.135_bb0500","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.2337\/diacare.27.9.2234","article-title":"Cardiovascular disease risk factors predict the development of type 2 diabetes: the insulin resistance atherosclerosis study","volume":"27","author":"D'Agostino","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.thromres.2018.02.135_bb0505","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1161\/01.CIR.89.1.321","article-title":"Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential risk factor for vascular disease","volume":"89","author":"Nordt","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2018.02.135_bb0510","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1182\/blood.V96.13.4212","article-title":"Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery","volume":"96","author":"Eitzman","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2018.02.135_bb0515","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1161\/01.ATV.9.1.109","article-title":"Identification and distribution of fibrinogen, fibrin, and fibrin(ogen) degradation products in atherosclerosis. Use of monoclonal antibodies","volume":"9","author":"Bini","year":"1989","journal-title":"Arteriosclerosis"},{"key":"10.1016\/j.thromres.2018.02.135_bb0520","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0021-9150(92)90069-S","article-title":"Substrate-bound fibrinogen, fibrin and other cell attachment-promoting proteins as a scaffold for cultured vascular smooth muscle cells","volume":"96","author":"Naito","year":"1992","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.thromres.2018.02.135_bb0525","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.2174\/138945011797635803","article-title":"Effects of altered plasminogen activator inhibitor-1 expression on cardiovascular disease","volume":"12","author":"Ploplis","year":"2011","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.thromres.2018.02.135_bb0530","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1161\/01.CIR.0000023186.60090.FB","article-title":"Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1","volume":"106","author":"Eren","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2018.02.135_bb0535","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.ijcard.2014.11.001","article-title":"Circulating acute phase proteins in relation to extent and composition of coronary atherosclerosis and cardiovascular outcome: results from the ATHEROREMO-IVUS study","volume":"177","author":"Battes","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.thromres.2018.02.135_bb0545","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2174\/187152911795945169","article-title":"Pathogenesis of neointima formation following vascular injury, cardiovascular & haematological disorders - drug targets","volume":"11","author":"Pourdjabbar","year":"2011","journal-title":"Cardiovasc. Hematol. Disord. Drug Targets"},{"key":"10.1016\/j.thromres.2018.02.135_bb0550","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/heartjnl-2013-304933","article-title":"Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography","volume":"100","author":"Cassese","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.thromres.2018.02.135_bb0555","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1161\/CIRCINTERVENTIONS.114.001341","article-title":"Clinical presentation and outcomes of coronary in-stent restenosis across 3-stent generations","volume":"7","author":"Magalhaes","year":"2014","journal-title":"Circ. Cardiovasc. Interv."},{"key":"10.1016\/j.thromres.2018.02.135_bb0560","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1538-7836.2007.02884.x","article-title":"Plasminogen activator inhibitor-1 predicts coronary in-stent restenosis of drug-eluting stents","volume":"6","author":"Katsaros","year":"2008","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2018.02.135_bb0565","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1093\/eurheartj\/ehv511","article-title":"Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Gruntzig Lecture ESC 2014","volume":"36","author":"Byrne","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.thromres.2018.02.135_bb0570","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1056\/NEJMoa1509038","article-title":"Everolimus-eluting bioresorbable scaffolds for coronary artery disease","volume":"373","author":"Ellis","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2018.02.135_bb0575","doi-asserted-by":"crossref","first-page":"5333","DOI":"10.1016\/j.biomaterials.2003.12.033","article-title":"Molecular responses of vascular smooth muscle cells and phagocytes to curcumin-eluting bioresorbable stent materials","volume":"25","author":"Nguyen","year":"2004","journal-title":"Biomaterials"},{"key":"10.1016\/j.thromres.2018.02.135_bb0580","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1016\/j.jacc.2006.08.035","article-title":"Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease. A randomized controlled trial","volume":"48","author":"Kandzari","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.thromres.2018.02.135_bb0585","doi-asserted-by":"crossref","first-page":"E296","DOI":"10.25011\/cim.v38i5.25686","article-title":"Does stent strut design impact clinical outcomes: comparative safety and efficacy of endeavor resolute versus resolute integrity zotarolimus-eluting stents","volume":"38","author":"Di Santo","year":"2015","journal-title":"Clin. Invest. Med."},{"key":"10.1016\/j.thromres.2018.02.135_bb0590","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.ijcard.2013.01.234","article-title":"Three year clinical outcomes with zotarolimus (Endeavor) drug-eluting stents in an unrestricted contemporary practice","volume":"168","author":"Giles","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.thromres.2018.02.135_bb0595","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1161\/01.ATV.0000215982.14003.b7","article-title":"Plasminogen activator inhibitor-1 from bone marrow-derived cells suppresses neointimal formation after vascular injury in mice","volume":"26","author":"Schafer","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.thromres.2018.02.135_bb0600","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1161\/01.CIR.100.15.1616","article-title":"Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis","volume":"100","author":"Strauss","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2018.02.135_bb0605","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0049-3848(01)00360-7","article-title":"Postprocedural PAI-1 activity is a risk marker of subsequent clinical restenosis in patients both with and without stent implantation after elective balloon PTCA","volume":"104","author":"Prisco","year":"2001","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2018.02.135_bb0610","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","article-title":"A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators","volume":"339","author":"Leon","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2018.02.135_bb0615","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJM199604253341702","article-title":"A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents","volume":"334","author":"Sch\u00f6mig","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2018.02.135_bb0620","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/01.ATV.0000254677.12861.b8","article-title":"Antiproliferative agents alter vascular plasminogen activator inhibitor-1 expression: a potential prothrombotic mechanism of drug-eluting stents","volume":"27","author":"Muldowney","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.thromres.2018.02.135_bb0625","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1161\/01.CIR.91.4.1175","article-title":"Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody","volume":"91","author":"Biemond","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2018.02.135_bb0630","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1021\/jm049766q","article-title":"Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization","volume":"47","author":"Elokdah","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.thromres.2018.02.135_bb0635","doi-asserted-by":"crossref","DOI":"10.1038\/srep36462","article-title":"Characterization of the Annonaceous acetogenin, annonacinone, a natural product inhibitor of plasminogen activator inhibitor-1","volume":"6","author":"Pautus","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.thromres.2018.02.135_bb0640","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1517\/13543776.2013.782393","article-title":"Plasminogen activator inhibitor-1 inhibitors: a patent review (2006\u2013present)","volume":"23","author":"Fortenberry","year":"2013","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.thromres.2018.02.135_bb0645","doi-asserted-by":"crossref","DOI":"10.4172\/1747-0862.1000125","article-title":"Chemical antagonists of plasminogen activator inhibitor-1: mechanisms of action and therapeutic potential in vascular disease","volume":"8","author":"Simone","year":"2014","journal-title":"J. Mol. Genet. Med."},{"key":"10.1016\/j.thromres.2018.02.135_bb0650","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1124\/jpet.105.084129","article-title":"Evaluation of PAI-039 [{1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic acid], a novel plasminogen activator inhibitor-1 inhibitor, in a canine model of coronary artery thrombosis","volume":"314","author":"Hennan","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.thromres.2018.02.135_bb0655","doi-asserted-by":"crossref","first-page":"9288","DOI":"10.1074\/jbc.M611642200","article-title":"Mechanism of inactivation of plasminogen activator inhibitor-1 by a small molecule inhibitor","volume":"282","author":"Gorlatova","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.thromres.2018.02.135_bb0660","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1111\/j.1538-7836.2008.03063.x","article-title":"Effect of tiplaxtinin (PAI-039), an orally bioavailable PAI-1 antagonist, in a rat model of thrombosis","volume":"6","author":"Hennan","year":"2008","journal-title":"J. Thromb. Haemost."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384818302007?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384818302007?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T04:28:00Z","timestamp":1693542480000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384818302007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":131,"alternative-id":["S0049384818302007"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2018.02.135","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of plasminogen activator inhibitor-1 in coronary pathophysiology","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2018.02.135","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}